… to determine celecoxib sensitivity, several predictors of gefitinib … In conclusion, this study
combining gefitinib with celecoxib … of chemotherapy in a similar patient population. As such, we …

… The primary objective of this study was to assess the response rate with the combination
of gefitinib and celecoxib in NSCLC patients designated as platinum refractory, based on …

… Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell
lung cancer (NSCLC): A phase II study from the Hoosier Oncology Group [abstract 7066]. …

… patients in the tribute trial with available tissue showed an increase in time to progression for
erlotinib plus pa… an egfr inhibitor in molecularly selected patients with stage iiib/iv nsclc. One …

… kinase inhibitors gefitinib and erlotinib. Although most … consecutive chemotherapy-naive
patients with advanced stage … et al 143 enrolled 452 patients with stages IIIB – IV NSCLC who …

… 561 chemotherapy-naïve, advanced-staged NSCLC patients … 1 every 21 days with or without
celecoxib 400 mg orally bid … that erlotinib and gefitinib have similar activity in patients with …

… , 53 eligible chemotherapy-naive patients with stage IIIB/IV NSCLC received oral erlotinib (…
but a positive predictor for survival in patients receiving celecoxib, but due to the small sample …

… chemotherapy-naïve, stage IIIA/B NSCLC patients were treated with cisplatin (80 mg/m 2
day 1) plus … II trial of erlotinib with or without celecoxib is underway in patients with recurrent …

… , celecoxib, a selective cyclooxygenase 2 inhibitor with antiangiogenic activity is being tested
in combination with erlotinib … stage IIIB/IV incurable NSCLC; performance status 3 patients …

… paclitaxel/carboplatin with celecoxib versus 13 controls who … in 2000 chemotherapy-naive
patients with advanced stage III/… erlotinib plus standard chemotherapy in patients with stage …